Cytosorbents Statistics
Share Statistics
Cytosorbents has 62.61M
shares outstanding. The number of shares has increased by 0.96%
in one year.
| Shares Outstanding | 62.61M |
| Shares Change (YoY) | 0.96% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 28.15% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 1.51M, so 2.4% of the outstanding
shares have been sold short.
| Short Interest | 1.51M |
| Short % of Shares Out | 2.4% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 21.97 |
Valuation Ratios
The PE ratio is -2.39 and the forward
PE ratio is -12.29.
Cytosorbents's PEG ratio is
0.06.
| PE Ratio | -2.39 |
| Forward PE | -12.29 |
| PS Ratio | 1.39 |
| Forward PS | 0.4 |
| PB Ratio | 4.46 |
| P/FCF Ratio | -3.37 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytosorbents.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.2,
with a Debt / Equity ratio of 2.42.
| Current Ratio | 2.2 |
| Quick Ratio | 1.92 |
| Debt / Equity | 2.42 |
| Debt / EBITDA | -1.4 |
| Debt / FCF | -1.83 |
| Interest Coverage | -12 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $238,889.4 |
| Profits Per Employee | $-139,053.4 |
| Employee Count | 149 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 3.83 |
Taxes
| Income Tax | -1.69M |
| Effective Tax Rate | 7.55% |
Stock Price Statistics
The stock price has increased by -6.67% in the
last 52 weeks. The beta is 1.18, so Cytosorbents's
price volatility has been higher than the market average.
| Beta | 1.18 |
| 52-Week Price Change | -6.67% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 39.74 |
| Average Volume (20 Days) | 102,429 |
Income Statement
In the last 12 months, Cytosorbents had revenue of 35.59M
and earned -20.72M
in profits. Earnings per share was -0.38.
| Revenue | 35.59M |
| Gross Profit | 25.13M |
| Operating Income | -16.79M |
| Net Income | -20.72M |
| EBITDA | -19.26M |
| EBIT | -21.01M |
| Earnings Per Share (EPS) | -0.38 |
Full Income StatementBalance Sheet
The company has 3.28M in cash and 26.89M in
debt, giving a net cash position of -23.61M.
| Cash & Cash Equivalents | 3.28M |
| Total Debt | 26.89M |
| Net Cash | -23.61M |
| Retained Earnings | -304.01M |
| Total Assets | 50.78M |
| Working Capital | 15.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -14.43M
and capital expenditures -284.34K, giving a free cash flow of -14.71M.
| Operating Cash Flow | -14.43M |
| Capital Expenditures | -284.34K |
| Free Cash Flow | -14.71M |
| FCF Per Share | -0.27 |
Full Cash Flow StatementMargins
Gross margin is 70.59%, with operating and profit margins of -47.16% and -58.21%.
| Gross Margin | 70.59% |
| Operating Margin | -47.16% |
| Pretax Margin | -62.96% |
| Profit Margin | -58.21% |
| EBITDA Margin | -54.11% |
| EBIT Margin | -47.16% |
| FCF Margin | -41.33% |
